Norman Gaylis

2.0k total citations · 1 hit paper
35 papers, 1.2k citations indexed

About

Norman Gaylis is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Norman Gaylis has authored 35 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Rheumatology, 10 papers in Hematology and 8 papers in Immunology. Recurrent topics in Norman Gaylis's work include Rheumatoid Arthritis Research and Therapies (22 papers), Systemic Lupus Erythematosus Research (12 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Norman Gaylis is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (22 papers), Systemic Lupus Erythematosus Research (12 papers) and Autoimmune and Inflammatory Disorders Research (10 papers). Norman Gaylis collaborates with scholars based in United States, Germany and Switzerland. Norman Gaylis's co-authors include Robert Landewé, Frederick T. Murphy, Eric L. Matteson, Mittie K. Doyle, Jonathan Kay, Yiying Zhou, Elizabeth C. Hsia, J. Wollenhaupt, Josef S Smolen and Sudha Visvanathan and has published in prestigious journals such as The Lancet, Clinical Infectious Diseases and Annals of the Rheumatic Diseases.

In The Last Decade

Norman Gaylis

34 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

2009 423 citations Josef S Smolen, Jonathan Kay et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Norman Gaylis United States	16	866	382	285	219	143	35	1.2k
Éric Houvenagel France	20	622 0.7×	188 0.5×	227 0.8×	88 0.4×	166 1.2×	68	1.3k
Kalliopi Fragiadaki Greece	18	686 0.8×	160 0.4×	437 1.5×	121 0.6×	234 1.6×	26	1.4k
Yasser Emad Egypt	18	493 0.6×	154 0.4×	256 0.9×	50 0.2×	70 0.5×	65	1.0k
Patrick J. Oliverio United States	11	363 0.4×	159 0.4×	192 0.7×	46 0.2×	143 1.0×	15	896
Silje Watterdal Syversen Norway	17	715 0.8×	114 0.3×	222 0.8×	79 0.4×	71 0.5×	39	1.2k
Rosario Foti Italy	16	427 0.5×	170 0.4×	183 0.6×	76 0.3×	133 0.9×	93	986
Ignasi Rodríguez‐Pintó Spain	18	996 1.2×	573 1.5×	273 1.0×	52 0.2×	62 0.4×	44	1.4k
Laura Durcan Ireland	15	778 0.9×	129 0.3×	549 1.9×	60 0.3×	111 0.8×	33	1.3k
Ewa Olech United States	17	529 0.6×	172 0.5×	240 0.8×	81 0.4×	89 0.6×	30	805
Debbie Campbell United States	9	581 0.7×	84 0.2×	648 2.3×	270 1.2×	196 1.4×	13	1.5k

Countries citing papers authored by Norman Gaylis

Since Specialization

Citations

This map shows the geographic impact of Norman Gaylis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norman Gaylis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norman Gaylis more than expected).

Fields of papers citing papers by Norman Gaylis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norman Gaylis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norman Gaylis. The network helps show where Norman Gaylis may publish in the future.

Co-authorship network of co-authors of Norman Gaylis

This figure shows the co-authorship network connecting the top 25 collaborators of Norman Gaylis. A scholar is included among the top collaborators of Norman Gaylis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norman Gaylis. Norman Gaylis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gaylis, Norman, David Sikes, Alan Kivitz, et al.. (2025). Neuroimmune Modulation for Drug-Refractory Rheumatoid Arthritis: Long-Term Safety and Efficacy in Patients Enrolled in a Pilot Vagus Nerve Stimulation Study. Rheumatology and Therapy. 12(6). 1125–1136.

Gaylis, Norman, et al.. (2024). ‘Totality of Evidence’ Approach in the Development of GP2017, an Approved Adalimumab Biosimilar. Advances in Therapy. 41(5). 1795–1814. 2 indexed citations

Gaylis, Norman, et al.. (2022). The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID. Frontiers in Nutrition. 9. 1034169–1034169. 7 indexed citations

Gaylis, Norman, Angela Ritter, Scott A. Kelly, et al.. (2022). Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome. Clinical Infectious Diseases. 75(7). 1232–1234. 16 indexed citations

Wiland, Piotr, et al.. (2020). Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA Study. BioDrugs. 34(6). 809–823. 31 indexed citations

Wiland, Piotr, et al.. (2019). FRI0087 EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB (REFADL) TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS (RA). Annals of the Rheumatic Diseases. 78. 706–707. 5 indexed citations

Gaylis, Norman, et al.. (2015). AB0503 The Effect of Corticotropin (ACTH 80 Units Weekly or Biweekly) in Combination with MTX in Newly Diagnosed RA Patients from a Clinical and Structural Perspective as Measured by a CDAI Score and Osteitis, Synovitis, and Erosions on MRI. Annals of the Rheumatic Diseases. 74. 1066–1067. 7 indexed citations

Greenwald, Maria, Joel M. Kremer, Norman Gaylis, et al.. (2014). Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study. BMC Musculoskeletal Disorders. 15(1). 177–177. 29 indexed citations

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2014). 85. Final 5-Year Safety and Efficacy Results of a Phase 3, Randomized, Placebo-Controlled Trial of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy. Lara D. Veeken. 53(suppl_1). i87–i88. 2 indexed citations

10.

Peterfy, Charles, Ewa Olech, Julie C. DiCarlo, et al.. (2013). Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Research & Therapy. 15(2). R44–R44. 33 indexed citations

11.

Conaghan, Philip G., Mikkel Østergaard, Maria Antonietta D’Agostino, et al.. (2013). Proceedings from the 5th Annual International Society for Musculoskeletal Imaging in Rheumatology Annual Conference. Seminars in Arthritis and Rheumatism. 42(4). 433–446. 1 indexed citations

12.

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2013). THU0202 Five-Year Safety and Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Despite Previous Anti-Tumor Necrosis Factor Therapy: Final Study Results of the Phase 3, Randomized, Placebo-Controlled Go-After Trial. Annals of the Rheumatic Diseases. 72. A232–A232. 2 indexed citations

13.

Peterfy, Charles, et al.. (2012). Evaluating joint-space narrowing and cartilage loss in rheumatoid arthritis by using MRI. Arthritis Research & Therapy. 14(3). R131–R131. 34 indexed citations

14.

Smolen, Josef S, Jonathan Kay, Robert Landewé, et al.. (2012). Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160. Annals of the Rheumatic Diseases. 71(10). 1671–1679. 49 indexed citations

15.

Peterfy, Charles, P.J. Countryman, Annarita Gabriele, et al.. (2011). Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience. The Journal of Rheumatology. 38(9). 2023–2030. 17 indexed citations

16.

Gaylis, Norman, et al.. (2009). In-office magnetic resonance imaging to monitor responses to therapy in rheumatoid arthritis. Rheumatology International. 30(2). 269–273. 3 indexed citations

17.

Smolen, Josef S, Jonathan Kay, Mittie K. Doyle, et al.. (2009). Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. The Lancet. 374(9685). 210–221. 423 indexed citations breakdown →

18.

Gaylis, Norman, et al.. (2007). Comparison of in-office magnetic resonance imaging versus conventional radiography in detecting changes in erosions after one year of infliximab therapy in patients with rheumatoid arthritis. Modern Rheumatology. 17(4). 273–278. 13 indexed citations

19.

Furst, D E, Norman Gaylis, Ewa Olech, et al.. (2007). Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Annals of the Rheumatic Diseases. 66(7). 893–899. 88 indexed citations

20.

Quencer, R M, et al.. (1982). Cerebral atrophy in systemic lupus erythematosus: steroid- or disease-induced phenomenon?. PubMed. 3(1). 21–3. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact